The new initiative, called MEGA+, will extend the process of genomic data sharing to all medical data, including electronic health records and imaging files.
The project plans to sequence 20,000 genomes in 2019, 50,000 by the end of 2020, and a total of 100,000 by the end of 2021 using Oxford Nanopore's PromethIon platform.
Evotec will access Indivumed's IndivuType multi-omics cancer database to discover and develop new precision therapeutics for colorectal cancer.
The companies will use their respective technologies to optimize the cannabinoid profiles and other traits of different cannabis varieties.
A NorthShore University HealthSystem and Color pilot picked up pathogenic variants in nearly 9 percent of unselected individuals with a hereditary cancer gene test.
The test will be designed to detect a protein biomarker in aqueous humor that can be used to determine the severity of glaucoma and to make treatment decisions.
LUNGevity will promote the donation of excess lung cancer tissue and fluid samples to boost the Broad's efforts to develop next-generation research models.
Decipher — formerly GenomeDx Biosciences — will help Dendreon identify patients who are likely to respond to its prostate cancer therapy Provenge.
The five-year deal, which is being funded by UCB, will focus in particular on epilepsy patients who do not respond to currently available treatments.
The R&D collaboration will examine a Western Digital theory that moving computational power closer to large genomic datasets can speed up analysis.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.